Ulcerative colitis in a child is a diagnosis that comes with a great deal of adjustment – for the child, who may have been unwell for months before diagnosis and who now learns they have a condition they will carry through life, and for the family, who take on the practical management of a condition that affects daily routines, diet, school attendance, and how the child relates to their body and to social situations.
What is worth understanding from the outset is that while UC is a chronic condition, it is not typically a life-shortening one, and that management has improved substantially over the past two decades. Many children and adults with UC have long periods of remission and lead entirely normal lives. The goal of treatment is precisely this: to achieve and maintain remission, and to do so with medications whose burden is as light as possible.
Healthbooq (healthbooq.com/apps/healthbooq-kids) covers chronic health conditions in children and families.
What Ulcerative Colitis Is
Ulcerative colitis is a type of inflammatory bowel disease (IBD) – a group of conditions characterised by chronic, relapsing inflammation of the gastrointestinal tract. In UC, inflammation is confined to the mucosal lining of the colon (large intestine) and rectum, beginning at the rectum and extending continuously towards the caecum. The extent of inflammation at diagnosis is described as proctitis (rectum only), left-sided colitis, or pancolitis (the entire colon) – and extent matters because it influences treatment choice and colitis risk.
UC is distinguished from Crohn's disease – the other main type of IBD – by its distribution (always colonic, always mucosal) compared with Crohn's, which can affect any part of the gastrointestinal tract from mouth to anus and may penetrate through the full bowel wall.
Around 25% of people with UC are diagnosed before the age of 18. Paediatric-onset UC tends to present with more extensive disease (pancolitis) than adult-onset UC, which is associated with a more aggressive disease course. The paediatric IBD research group led by Richard Russell at the University of Glasgow and the British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) have produced the standards for UK paediatric IBD management.
Causes and Triggers
The cause of UC is not fully understood but involves a dysregulated immune response to the gut microbiome in genetically susceptible individuals. Genetic factors are important: a child with a parent with UC has around a 5-10 fold higher risk of developing the condition. Genome-wide association studies have identified over 200 genetic loci associated with IBD risk. Environmental factors – diet, early antibiotic use, hygiene, smoking (which paradoxically appears protective in UC, unlike in Crohn's) – contribute to risk.
Relapse in established disease can be triggered by gastrointestinal infections, antibiotic use, NSAID use, smoking cessation, and stress, though triggers vary between individuals.
Symptoms
The hallmark symptoms of active UC are bloody diarrhoea (blood mixed with or coating the stool), urgency (the need to get to the toilet quickly), frequency (multiple bowel movements per day, often more than six in a severe flare), and tenesmus (a feeling of incomplete evacuation). Abdominal cramps are common; fatigue during flares can be severe and is often underappreciated in both clinical and educational settings.
During remission, most children have completely normal bowel function. Extra-intestinal manifestations – joint pains (arthropathy), skin conditions (erythema nodosum, pyoderma gangrenosum), eye inflammation (episcleritis, uveitis), and liver disease (primary sclerosing cholangitis, which is more common in UC than Crohn's) – affect a proportion of children with UC and may precede, coincide with, or occur independently of gut inflammation.
Diagnosis
Diagnosis requires a combination of clinical assessment, blood and stool tests, and endoscopy. A colonoscopy with biopsies is the definitive diagnostic investigation, allowing direct visualisation of the colonic mucosa and histological confirmation of inflammation. Calprotectin (a protein released from inflamed gut mucosa into the stool) is a useful non-invasive marker for monitoring disease activity and distinguishing IBD from functional conditions like IBS.
Treatment
Treatment in UC aims to induce remission in active disease and maintain remission long-term, using the least medication necessary to achieve this.
Aminosalicylates (mesalazine – a 5-ASA compound) are first-line for mild-to-moderate UC. In proctitis, rectal suppositories or enemas deliver the medication directly to the inflamed mucosa; for more extensive disease, oral mesalazine is used. Mesalazine has a good long-term safety profile and most children tolerate it well.
Corticosteroids (oral prednisolone or intravenous hydrocortisone in acute severe UC) are used to rapidly induce remission during flares but are not appropriate for long-term maintenance due to side effects.
Thiopurines (azathioprine or 6-mercaptopurine) are immunomodulators used for maintenance in those who require frequent steroid courses or who have steroid-dependent disease. They take several months to take full effect and require monitoring for bone marrow suppression and hepatotoxicity.
Biologic therapies – anti-TNF agents (infliximab, adalimumab) and anti-integrin agents (vedolizumab) – are used for moderate-to-severe UC or for those who fail conventional treatment. Infliximab is well-established in paediatric UC and has been shown to induce remission and reduce the need for surgery. JAK inhibitors (tofacitinib, upadacitinib) represent newer small-molecule alternatives for adolescents with refractory disease.
Colectomy (surgical removal of the colon) is curative for UC – unlike Crohn's, where surgery does not cure the underlying condition – and is used for fulminant or toxic colitis (a medical emergency), for disease refractory to medical management, and for dysplasia or colorectal cancer risk (after long-standing extensive colitis). A restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred procedure where possible, creating an internal reservoir from the small intestine.
School and Daily Life
Ulcerative colitis during active flares affects school attendance significantly: urgency and frequency make it difficult to leave the house, and fatigue can be severe. Schools should be made aware of the diagnosis and should allow unrestricted toilet access and flexibility around attendance and deadlines during flares. For children with significant school impact, an EHC plan or EHCP may be appropriate. Crohn's & Colitis UK provides school cards that briefly explain IBD for discreet use when a child needs urgent toilet access.
Key Takeaways
Ulcerative colitis (UC) is a chronic inflammatory bowel disease affecting the colon, characterised by periods of active inflammation (flares) and remission. Around 25% of people with UC are diagnosed in childhood or adolescence, and paediatric UC often presents with more extensive disease than adult-onset UC. Symptoms include bloody diarrhoea, abdominal cramps, urgency, and fatigue. Treatment aims to induce and maintain remission using aminosalicylates (mesalazine), immunomodulators, and biologics; surgery to remove the colon is curative but reserved for severe or refractory disease. With good management, most children with UC live full, active lives.
